Last reviewed · How we verify
NCT03579082
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Status unknown
Phase 4
Last updated 14 September 2018
What this trial tests
Phase 4 trial testing Decitabine in Diffuse Large B Cell Lymphoma in 60 participants. Status unknown.
Timeline
1 June 2018
Primary endpoint
1 June 2019
1 June 2019
1 December 2019
Quick facts
| Lead sponsor | Mingzhi Zhang |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 June 2018 |
| Primary completion | 1 June 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Decitabine (decitabine) — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
Sponsor
Mingzhi Zhang — full company profile →
Who can join
Adults 14 to 65, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0 -
Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N, Ma T, Yu B, Yu B. · · 2023 · cited 213× · PMID 36797239 · DOI 10.1038/s41392-023-01341-7 -
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x -
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2 -
The paradigm of drug resistance in cancer: an epigenetic perspective.
Adhikari S, Bhattacharya A, Adhikary S, Singh V, et al · · 2022 · cited 52× · PMID 35438143 · DOI 10.1042/bsr20211812 -
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.
Sarno F, Benincasa G, List M, Barabasi AL, et al · · 2021 · cited 49× · PMID 33785068 · DOI 10.1186/s13148-021-01047-z -
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.
Ribeiro ML, Reyes-Garau D, Armengol M, Fernández-Serrano M, et al · · 2019 · cited 20× · PMID 31681423 · DOI 10.3389/fgene.2019.00986 -
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
Serganova I, Chakraborty S, Yamshon S, Isshiki Y, et al · · 2021 · cited 19× · PMID 35071240 · DOI 10.3389/fcell.2021.805195
Verify or expand the search:
- PubMed search for NCT03579082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Decitabine
Trials testing the same drug.
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
- NCT07389239 — A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. · Phase 1, PHASE2 · not yet recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant · Phase 2 · recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
- NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
Other Mingzhi Zhang trials
Trials by the same sponsor.
- NCT06647329 — CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors · Phase 1 · not yet recruiting
- NCT06683885 — A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and · Phase 1, PHASE2 · recruiting
- NCT06559553 — "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL · Phase 1, PHASE2 · recruiting
- NCT04831658 — A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervou · Phase 1, PHASE2 · unknown
- NCT04083066 — Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous Sys · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03579082 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mingzhi Zhang
- Last refreshed: 14 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03579082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing